Title |
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
|
---|---|
Published in |
Blood, July 2003
|
DOI | 10.1182/blood-2003-05-1627 |
Pubmed ID | |
Authors |
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman, Heather C. Flynn, Sarah F. Paternoster, Brandon M. Shearer, Terra L. Reeder, Chin-Yang Li, Nicholas C.P. Cross, Jan Cools, D. Gary Gilliland, Gordon W. Dewald, Ayalew Tefferi |
Abstract |
Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFR beta- activating mutations. The drug is also active in a subset of patients with eosinophilic disorders and systemic mast cell disease (SMCD). Recently, a novel tyrosine kinase that is generated from fusion of the Fip1-like 1 (FIP1L1) and PDGFR alpha (PDGFRA) genes has been identified as a therapeutic target for imatinib mesylate in hypereosinophilic syndrome (HES). We used fluorescence in situ hybridization (FISH) to detect deletion of the CHIC2 locus at 4q12 as a surrogate for the FIP1L1-PDGFRA fusion. CHIC2 deletion was observed in bone marrow cells for 3 of 5 patients with SMCD associated with eosinophilia. Deletion of this locus and expression of the FIP1L1-platelet-derived growth factor receptor alpha (PDGFRA) fusion was also documented in enriched eosinophils, neutrophils, or mononuclear cells by both FISH and reverse transcriptase-polymerase chain reaction (RT-PCR) for one patient. While all 3 patients with the FIP1L1-PDGFRA rearrangement achieved a sustained complete response with imatinib mesylate therapy, the other two, both carrying the c-kit Asp816 to Val (Asp816Val) mutation, did not. These observations suggest that the FIP1L1-PDGFRA rearrangement occurs in an early hematopoietic progenitor and suggests that the molecular pathogenesis for a subset of SMCD patients is similar to that of HES. Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 3% |
Austria | 1 | 2% |
Unknown | 56 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 17% |
Student > Ph. D. Student | 8 | 14% |
Student > Bachelor | 6 | 10% |
Professor | 6 | 10% |
Student > Master | 6 | 10% |
Other | 11 | 19% |
Unknown | 12 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 36% |
Biochemistry, Genetics and Molecular Biology | 12 | 20% |
Agricultural and Biological Sciences | 9 | 15% |
Nursing and Health Professions | 2 | 3% |
Earth and Planetary Sciences | 1 | 2% |
Other | 3 | 5% |
Unknown | 11 | 19% |